Edition:
India

Transgene SA (TRNG.PA)

TRNG.PA on Paris Stock Exchange

2.93EUR
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
€2.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
37,182
52-wk High
€3.31
52-wk Low
€2.57

Latest Key Developments (Source: Significant Developments)

Transgene Secures A 20 Million Euros Revolving Credit Facility With Natixis
Monday, 18 Mar 2019 

March 18 (Reuters) - TRANSGENE SA ::TRANSGENE SECURES A €20 MILLION REVOLVING CREDIT FACILITY WITH NATIXIS.CREDIT FACILITY WILL HAVE A 30-MONTH TERM AND TRANSGENE WILL BE ABLE TO DRAW ON AND REPAY FACILITY AT ITS DISCRETION.CEO: "WITH THIS NEW LOAN FACILITY, WE NOW HAVE FUNDS NEEDED TO SUPPORT OUR CLINICAL AND PRE-CLINICAL ACTIVITIES UNTIL MID-2020".  Full Article

Transgene Announces NEOVIVA Project Is Awarded A Grant Of 5.2 Million Euros
Wednesday, 13 Mar 2019 

March 13 (Reuters) - TRANSGENE SA ::TRANSGENE - NEOVIVA PROJECT SUPPORTING THE DEVELOPMENT OF MYVAC™ AWARDED A €5.2 MILLION GRANT FROM BPIFRANCE’S “INVESTMENTS FOR THE FUTURE” PROGRAMME.NEOVIVA PROJECT WILL RECEIVE EUR 5.2 MILLION OVER FIVE-YEAR DURATION OF PROGRAM FROM BPIFRANCE, OF WHICH TRANSGENE WILL RECEIVE EUR 2.6 MILLION.TWO PROOF OF CONCEPT CLINICAL TRIALS ARE BEING PREPARED IN EUROPE AND US FOR TREATMENT OF HPV-NEGATIVE HEAD AND NECK CANCERS AND OVARIAN CANCER.THESE ARE EXPECTED TO START IN H2 2019.  Full Article

Transgene To Start Clinical Development Of TG4050
Tuesday, 5 Mar 2019 

March 5 (Reuters) - TRANSGENE SA ::TRANSGENE TO START CLINICAL DEVELOPMENT OF LEAD MYVACTM INDIVIDUALIZED IMMUNOTHERAPY, TG4050, IN 2019, UNDER ITS PARTNERSHIP WITH NEC.BOTH STUDIES WILL BE CO-FUNDED BY TRANSGENE AND NEC.TG4050 IS A NEOANTIGEN THERAPEUTIC VACCINE DEVELOPED FOR INDIVIDUAL PATIENTS, BASED ON SPECIFIC MUTATIONS IDENTIFIED IN PATIENT'S OWN TUMOR.TWO CLINICAL TRIALS IN OVARIAN CANCER AND HEAD AND NECK CANCER PATIENTS WILL START IN 2019.  Full Article

Transgene Completes Safety And Tolerability Assessment In Phase 1B Part Trial In Hpv-Positive Cancer Patients
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - TRANSGENE SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.ON TRACK WITH PHASE 2 PART OF STUDY: FIRST PATIENTS ENROLLED.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.  Full Article

Transgene Completes Safety And Tolerability Assessment Of TG4001
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Transgene SA ::TRANSGENE COMPLETES SAFETY AND TOLERABILITY ASSESSMENT OF TG4001 IN COMBINATION WITH AVELUMAB IN PHASE 1B PART OF TRIAL IN HPV-POSITIVE CANCER PATIENTS.OBJECTIVES FROM THE PHASE 1B STUDY SUCCESSFULLY MET.ON TRACK WITH THE PHASE 2 PART OF THE STUDY: FIRST PATIENTS ENROLLED.PRELIMINARY EFFICACY DATA EXPECTED IN 2H 2019.CLINICAL TRIAL IN COLLABORATION WITH MERCK KGAA, DARMSTADT, GERMANY, AND PFIZER.FIRST DATA FROM THIS TRIAL ON THE ACTIVITY OF THE COMBINATION ARE EXPECTED DURING THE SECOND HALF OF 2019..  Full Article

Transgene: Positive Results Of TG1050 Phase 1 Clinical Trial In Chronic Hepatitis B
Monday, 12 Nov 2018 

Nov 12 (Reuters) - TRANSGENE SA ::POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL OF TG1050 IN CHRONIC HEPATITIS B.PRIMARY END-POINT REACHED.TG1050 TRIGGERS T CELL-BASED IMMUNE RESPONSES.NEW PRECLINICAL DATA CLEARLY SUPPORT FURTHER INVESTIGATION OF TG1050 IN COMBINATION WITH ANTIVIRALS OR IMMUNOMODULATORS.NEW AND ENCOURAGING PRECLINICAL DATA SHOWING IMPROVED ANTIVIRAL ACTIVITY OF TG1050 WHEN ADMINISTERED IN COMBINATION WITH EITHER ANTIVIRALS OR IMMUNOMODULATORS IN HBV-PERSISTENT MICE.  Full Article

Transgene: Positive Results From Phase 1 Clinical Trial Of TG1050 In Chronic Hepatitis B
Monday, 12 Nov 2018 

Nov 12 (Reuters) - TRANSGENE SA ::TRANSGENE - POSITIVE RESULTS FROM PHASE 1 CLINICAL TRIAL OF TG1050 IN CHRONIC HEPATITIS B PRESENTED AT THE AASLD LIVER MEETING 2018.PRIMARY END-POINT REACHED.NEW PRECLINICAL DATA CLEARLY SUPPORT FURTHER INVESTIGATION OF TG1050 IN COMBINATION WITH ANTIVIRALS OR IMMUNOMODULATORS.TG1050 TRIGGERS T CELL-BASED IMMUNE RESPONSES, SPECIFIC OF ALL 3 ENCODED HBV ANTIGENS, CONFIRMING THE MECHANISM OF ACTION OF THE PRODUCT.  Full Article

Transgene Presents Data Supporting Myvac Platform
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - TRANSGENE SA ::TRANSGENE PRESENTS FIRST PRECLINICAL AND TRANSLATIONAL DATA SUPPORTING ITS NOVEL MYVAC™ PLATFORM.SET UP PROCESS AIMED AT DEVELOPING A MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED, INDIVIDUALIZED IMMUNOTHERAPY PRODUCT THAT RECOGNIZES AND DESTROYS TUMORS.IMMUNOGENICITY OF INDIVIDUALIZED VACCINE HAS BEEN DEMONSTRATED IN A HUMANIZED MICE MODEL..IMMUNE RESPONSE OBSERVED IN MICE MODEL PARTLY OVERLAPS WITH ONE OBSERVED IN HUMANS.  Full Article

Transgene Q3 Operating Revenue Up At 37.5 Million Euros
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - TRANSGENE SA ::CASH, CASH EQUIVALENTS, AND OTHER CURRENT FINANCIAL ASSETS STOOD AT €26.6 MILLION AS OF SEPTEMBER 30, 2018.CASH BURN IN LINE WITH EXPECTATIONS - COMPANY CONFIRMS FINANCIAL VISIBILITY UNTIL SEPTEMBER 2019.Q3 OPERATING REVENUE EUR 37.5 MILLION VERSUS EUR 1.6 MILLION YEAR AGO.  Full Article

Transgene Sells Greater China Rights Of TG6002 And TG1050 To Tasly Biopharmaceuticals
Monday, 20 Aug 2018 

Aug 20 (Reuters) - TRANSGENE SA ::COMPLETES THE SALE OF GREATER CHINA RIGHTS OF TG6002 AND TG1050 TO TASLY BIOPHARMACEUTICALS FOR $48 MILLION IN NEWLY-ISSUED SHARES.T601 AND T101 ARE NOW BEING DEVELOPED BY TASLY BIOPHARMACEUTICALS FOR PATIENTS IN GREATER CHINA.27.4 MILLION NEWLY-ISSUED SHARES OF TASLY BIOPHARMACEUTICALS HAVE BEEN DELIVERED TO TRANSGENE.TRANSGENE NOW HOLDS APPROXIMATELY 2.53% OF OUTSTANDING CAPITAL OF TASLY BIOPHARMACEUTICALS.  Full Article